USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS
- Resource Type
- article
- Authors
- V. R. Mkrtchyan; L. V. Brylev; I. A. Shpak; A. M. Sergeev
- Source
- Неврология, нейропсихиатрия, психосоматика, Vol 8, Iss 4, Pp 98-103 (2016)
- Subject
- multiple sclerosis
pharmacoeconomics
dimethyl fumarate
teriflunomide
fingolimod
natalizumab
Neurology. Diseases of the nervous system
RC346-429
- Language
- Russian
- ISSN
- 2074-2711
2310-1342
The paper presents a review of an update on the comparative pharmacoeconomic analysis of using dimethyl fumarate in the treatment of multiple sclerosis (MS) in European countries. A pharmacoeconomic evaluation was made to study the use of first-line oral dimethyl fumarate versus another first-line oral teriflunomide in the treatment of MS in the Russian Federation (for 1 year) and second-line natalizumab and fingolimod. Among first-line oral drugs, dimethyl fumarate was shown to be superior to teriflunomide in a cost-effectiveness ratio and to be slightly ahead of the MS-modifying drugs (MSMDs) and the second-line drugs natalizumab and fingolimod. According to clinical and economic indicators, dimethyl fumarate is the drug of choise among other MSMDs in the treatment of MS.